Delays in Reorganizing the Chinese Sales Network and Weak Sales in Emerging Markets
First written in FY2016-Q3. 26 of 29 entries say "Mitigated", first in FY2016. Latest entry: 2026-10-15.
The whole theme swung hardest in 2019: 15 of 34 companies on the "Worse" side.
10 other companies' latest entry also says "Mitigated".
- FY2026-H1MitigatedAnnual report
「Subsequently, following approval from the Chinese regulatory authorities on 29 October 2025, we officially resumed sales in November of the same year. Orders resumed from numerous customers, including distributors and end users, driven by vigorous activities by our Chinese sales subsidiary and other factors, and the recovery in business performance is progressing faster than expected.」
It states that sales of Dia-Bars have officially resumed and that business performance is recovering faster than expected as orders resume from numerous customers, despite sluggish sales through the Chinese distribution network and in emerging markets. - FY2025MaterialisedAnnual report
「Regarding the voluntary recall of MANI diamond burs in China... The voluntary recall began in March 2025 and was largely completed by August of the same year.」
In addition to the slowdown in the Chinese market and other factors, a voluntary recall of diamond burs was actually carried out because of deficiencies in the product registration information, and the recall was largely completed by August 2025. - FY2023-Q3MitigatedAnnual report
「Orders for eyeless needles continued to increase in Asia, North America, Europe and South America, resulting in substantial increases in revenue and profit.」
The company states that orders for eyeless needles increased in Asia, North America, Europe and South America compared with the previous weakness in emerging-market sales, resulting in substantial increases in revenue and profit. - FY2023-Q2MitigatedAnnual report
「Sales of dental root canal treatment instruments, including reamers and files, and dental rotary cutting instruments, including diamond burs, remained solid in Asia, particularly China and India. In addition, the weaker yen boosted earnings, resulting in higher revenue than in the same period of the previous year.」
Compared with the previous reorganization of the Chinese distribution network and weak sales in emerging markets, sales of dental products remained solid in Asia, particularly China and India. Revenue was ¥4,688 million, up 16.8% year on year. - FY2022-Q3MitigatedAnnual report
「Despite the impact of lockdowns in China, sales of diamond burs and other products remained strong in Asia, led by India, resulting in revenue of ¥6,079 million, up 9.0% year on year.」
The company states that, while China was affected by lockdowns, strong sales in Asia, led by India, resulted in 9.0% year-on-year growth in dental-related products. - FY2022-Q2MitigatedAnnual report
「As sales remained strong in China and Europe, revenue was ¥2,857 million, up 17.1% year on year. As sales of diamond burs and other products remained strong in Asia, including India, revenue was ¥4,013 million, up 11.8% year on year.」
The company states that sales remained strong in China and Europe, as well as in Asia, including India, compared with the previous reorganization of the Chinese distribution network and weak sales in emerging markets. - FY2022-Q1MitigatedAnnual report
「Sales rose in China and India, while sales in South Korea remained solid, among other factors. Revenue was ¥2,083 million, up 10.3% year on year.」
The company states that dental-related products posted higher revenue as sales expanded in China and India and remained solid in South Korea, despite the previous weakness in emerging-market sales. - FY2021MitigatedAnnual report
「Although sales remained solid in Asia, led by China, revenue was ¥5,044 million, down 0.2% year on year, as non-urgent surgeries were restricted because of the impact of COVID-19.」
Sales in Asia, led by China, were described as solid, indicating a recovery from the previous reorganization and weakness in the Chinese distribution network. However, restrictions on surgeries resulted in a 0.2% year-on-year decline in eyeless-needle-related products overall. - FY2021-Q3MitigatedAnnual report
「Sales of surgical-related and dental-related products increased, driven by China, where the market recovered quickly.」
For emerging-market sales that had been weak because of COVID-19 and other factors, the company states that sales in China drove revenue growth in surgical-related and dental-related products. - FY2021-Q2MitigatedAnnual report
「Sales of dental-related products increased, driven by China, where the market recovered relatively quickly and sales activities were gradually resuming as usual.」
For emerging-market sales that had been weak because of COVID-19 and other factors, the company states that the recovery of the Chinese market and the resumption of sales activities resulted in higher sales of dental-related products. - FY2021-Q1MitigatedAnnual report
「Sales of dental-related products increased, driven by sales in China. As sales of diamond burs and reamers and files grew in China, where the market recovered relatively quickly, revenue was ¥1,889 million, up 12.8% year on year.」
Compared with the previous year, when sales in China were particularly weak because of COVID-19 and other factors, the company states that sales of dental-related products in China increased 12.8% year on year. Sales of other product groups, however, continued to decline. - FY2020MaterialisedAnnual report
「In addition to the continuing effects of inventory adjustments at a major European customer since the previous fiscal year, surgeries at hospitals were temporarily restricted because of COVID-19. As sales, particularly in China, remained weak, revenue was ¥4,374 million, down 24.0% year on year.」
For emerging-market sales that had previously been improving, the overlap of inventory adjustments and restrictions on surgeries caused by COVID-19 was reflected in an actual decline in sales of eyeless-needle-related products, including in China. - FY2020-Q1MitigatedAnnual report
「The company was able to increase sales of dental-related products in China and India.」
The company states that sales of dental-related products increased in China and India, addressing previous concerns related to the reorganization of the Chinese distribution network and weak sales in emerging markets. - FY2019-Q3MitigatedAnnual report
「As a result of strengthening marketing centered on local sales bases, identifying user needs in each country and working to develop distribution networks, the company was able to increase sales of surgical-related and eyeless-needle-related products.」
The company states that sales of surgical-related and eyeless-needle-related products increased through the development of local distribution networks and other measures, despite the previous weakness in emerging-market sales. - FY2019-Q1MitigatedAnnual report
「Against this backdrop, the Group continued to strengthen marketing in emerging markets where demand is expected to expand, particularly in China, Vietnam and India, identify user needs in each country and work to develop distribution networks. As a result, sales in Asia remained strong, offsetting the decline in sales resulting from the transfer of shares in Schütz Dental GmbH and achieving revenue growth.」
Strong sales in Asia, particularly China, Vietnam and India, offset the decline in sales resulting from the transfer of shares in Schütz Dental GmbH, indicating that the effects of the previous weakness in emerging-market sales had eased. - FY2018MitigatedAnnual report
「The company was able to significantly increase sales of surgical-related products and eyeless-needle-related products.」
The company states that sales in multiple segments increased significantly despite the previous reorganization of the Chinese distribution network and weak sales in emerging markets. - FY2018-Q3MitigatedAnnual report
「As distribution reforms in the Chinese market progressed and sales of reamers and files in China remained strong,」
The company states that distribution reforms in the Chinese market progressed and sales of reamers and files in China remained strong, indicating that the effects of the reorganization and weakness in the Chinese distribution network continued to ease. - FY2018-Q2MitigatedAnnual report
「As distribution reforms in the Chinese market progressed and sales of reamers and files and diamond burs remained strong, revenue was ¥4,638 million, up 14.6% year on year.」
The company states that distribution reforms in the Chinese market progressed and sales of key dental products remained strong, indicating an improvement from the previous weakness in Chinese sales. - FY2018-Q1MitigatedAnnual report
「As a result of strengthening marketing centered on local sales bases, identifying user needs and working to develop the distribution network, sales in Asia remained strong.」
The company states that sales in Asia remained strong despite the previous reorganization of the Chinese distribution network and weak sales in emerging markets. - FY2017MitigatedAnnual report
「The company was able to significantly increase sales of dental-related and surgical-related products in China.」
The company states that sales of multiple products in China continued to increase despite the reorganization of the Chinese distribution network and weak sales in emerging markets. - FY2017-Q3MitigatedAnnual report
「The company was able to significantly increase sales of dental-related products in China.」
The company states that sales of dental-related products in China continued to increase despite the reorganization of the Chinese distribution network and weak sales in emerging markets. - FY2017-Q2MitigatedAnnual report
「The company was able to significantly increase sales of dental-related products in China.」
The company states that sales of dental-related products in China increased significantly compared with the previous weakness in Chinese sales, indicating that the effects of the distribution-network reorganization and weak sales in emerging markets continued to ease. - FY2017-Q1MitigatedAnnual report
「Sales of dental-related products in China remained strong.」
Although the company does not directly assess the effects of the reorganization of the Chinese distribution network, it states that sales in China remained strong compared with the previous weakness in Chinese sales. - FY2016MitigatedAnnual report
「As the effects of the reorganization of the Chinese distribution network gradually abated, revenue was ¥8,316 million, up 56.1% year on year.」
The company explains that the effects of the reorganization of the Chinese distribution network, previously cited as a factor behind weak sales, are gradually abating. - FY2016-Q3First statedAnnual report
「Overall performance remained weak due to the impact of the reorganization of the Chinese sales network and the downturn in emerging-market economies.」
States that the reorganization of the sales network and the downturn in emerging-market economies affected sales during the period.